Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

Leukemia

Volumn 28, Issue 2, 2014, Pages 241-247

  Haferlach, T ^a   Nagata, Y ^b,d   Grossmann, V ^a   Okuno, Y ^b   Bacher, U ^a   Nagae, G ^c   Schnittger, S ^a   Sanada, M ^b,d   Kon, A ^b,d   Alpermann, T ^a   Yoshida, K ^b,d   Roller, A ^a   Nadarajah, N ^a   Shiraishi, Y ^e   Shiozawa, Y ^b,d   Chiba, K ^e   Tanaka, H ^e   Koeffler, H P ^f,g   Klein, H U ^h   Dugas, M ^h   Aburatani, H ^c   Kohlmann, A ^a   Miyano, S ^e   Haferlach, C ^a   Kern, W ^a   Ogawa, S ^b,d   more..

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

molecular markers; myelodysplastic syndromes; next generation sequencing; prognostic score

Indexed keywords

ASXL1 PROTEIN; DNA METHYLTRANSFERASE 3A; SF3B1 PROTEIN; SRSF2 PROTEIN; TET METHYLCYTOSINE DIOXYGENASE 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE DELETION; GENE MUTATION; GENETIC HETEROGENEITY; GENOME ANALYSIS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84893772765     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.336     Document Type: Article

References (33)

1. Brunning R, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I et al. Myelodysplastic syndromes. In: Swerdlow S, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H et al. (eds). 4 edn, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008, pp 87-93.
2. Cazzola M, la Porta MG, Travaglino E, Malcovati L. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol 2011; 38: 627-634.
3. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
4. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
5. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
6. Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011; 29: 504-515.
7. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
8. Mardis ER. New strategies and emerging technologies for massively parallel sequencing: applications in medical research. Genome Med 2009; 1: 40.
9. Yoshida K, Sanada M, Kato M, Kawahata R, Matsubara A, Takita J et al. A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Leukemia 2011; 25: 184-186.
10. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433.
11. Gelsi-Boyer V, Trouplin V, Roquain J, Adelaide J, Carbuccia N, Esterni B et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010; 151: 365-375.
12. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
13. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665-667.
14. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
15. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
16. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012; 44: 53-57.
17. Walter MJ, Shen D, Shao J, Ding L, White B, Kandoth C et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013; 27: 1275-1282.
18. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090-1098.
19. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; e-pub ahead of print 12 September 2013; doi:10.1182/blood-2013-08-518886.
20. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
21. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30: 3376-3382.
22. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, del Canizo C et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943-2964.
23. Metzker ML. Sequencing technologies-the next generation. Nat Rev Genet 2010; 11: 31-46.
24. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11: 685-696.
25. Tibshirani R. Regression shrinkage and selection via the Lasso. J Royal Statist Soc B 1996; 58: 267-288.
26. Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biom J 2010; 52: 70-84.
27. Davidson R, Mackinnon JG. Several tests for model specification in the presence of alternative hypotheses. Econometrica 1981; 49: 781-793.
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300.
29. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu KS, Jerez A et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119: 3203-3210.
30. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278.
31. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259: 968-971.
32. Boultwood J, Fidler C, Lewis S, MacCarthy A, Sheridan H, Kelly S et al. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q-chromosome in some patients with the 5q-syndrome. Blood 1993; 82: 2611-2616.
33. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman J et al. Myelodysplastic syndromes. In: Jaffe ES, Harris N, Stein H, Vardiman J (eds). World Health Organization of Tumors, Pathology & Genetics, Tumors of haematopoietic and lymphoid tissues. IARC Press: Lyon, France, 2001, pp 61-73.